|Targets||Neurokinin 1 Receptor|
|Description||FR 113680 is a novel tripeptide substance P antagonist with NK1 receptor selectivity originated by Fujisawa for the treatment of Asthma. But no development are reported yet.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator: Fujisawa|
Telmapitant is a neurokinin NK1 receptor antagonist.
Serlopitant is a Neurokinin 1 (NK-1) receptor antagonist. Phase II clinical trials for the treatment of Prurigo nodularis and Pruritus are on-going.
Orvepitant is a potent and selective Neurokinin-1 (NK1) antagonist. It may be potential therapeutic for the treatment of patients with major depressive disorder...
Fosnetupitant, a piperazine derivative, has been found to be a NK1 receptor antagonist that could be used in nausea and vomiting caused by chemotherapy. It was ...
The dihydrochloride salt form of Vofopitant, a tetrazole compound, has been found to be a neurokinin 1 antagonist that was once studied inbBipolar disorders as ...
Ibodutant is a tachykinin receptor antagonist. It selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations...
FR 113680 is a novel tripeptide substance P antagonist with NK1 receptor selectivity originated by Fujisawa for the treatment of Asthma. But no development are ...
Casopitant Mesylate is a potent, selective and orally active neurokinin 1 (NK1) receptor antagonist binding of the endogenous tachykinin neuropeptide substance ...
Orvepitant maleate is a neurokinin-1 (NK1) receptor antagonist developed for the treatment of depression and anxiety disease.